LV10505B - Method for the production of erytropoietin - Google Patents

Method for the production of erytropoietin Download PDF

Info

Publication number
LV10505B
LV10505B LVP-93-500A LV930500A LV10505B LV 10505 B LV10505 B LV 10505B LV 930500 A LV930500 A LV 930500A LV 10505 B LV10505 B LV 10505B
Authority
LV
Latvia
Prior art keywords
die
der
epo
das
von
Prior art date
Application number
LVP-93-500A
Other languages
English (en)
Latvian (lv)
Other versions
LV10505A (lv
Inventor
Edward Fritsch
Rodney M Hewick
Kenneth Jacobs
Original Assignee
Genetics Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27418329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV10505(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Inst filed Critical Genetics Inst
Publication of LV10505A publication Critical patent/LV10505A/xx
Publication of LV10505B publication Critical patent/LV10505B/lv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
LVP-93-500A 1984-12-04 1993-06-08 Method for the production of erytropoietin LV10505B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67781384A 1984-12-04 1984-12-04
US68862285A 1985-01-03 1985-01-03
US69325885A 1985-01-22 1985-01-22
PCT/US1985/002405 WO1986003520A1 (en) 1984-12-04 1985-12-03 Method for the production of erythropoietin

Publications (2)

Publication Number Publication Date
LV10505A LV10505A (lv) 1995-02-20
LV10505B true LV10505B (en) 1996-04-20

Family

ID=27418329

Family Applications (2)

Application Number Title Priority Date Filing Date
LVP-93-500A LV10505B (en) 1984-12-04 1993-06-08 Method for the production of erytropoietin
LVP-93-623A LV10507B (lv) 1984-12-04 1993-06-10 Vektors, šūnas, eritropoetins,farmaceitiskā kompozīcija

Family Applications After (1)

Application Number Title Priority Date Filing Date
LVP-93-623A LV10507B (lv) 1984-12-04 1993-06-10 Vektors, šūnas, eritropoetins,farmaceitiskā kompozīcija

Country Status (24)

Country Link
EP (2) EP0411678B2 (sv)
JP (4) JPH02104284A (sv)
KR (1) KR890001011B1 (sv)
AT (2) ATE71408T1 (sv)
AU (1) AU621535B2 (sv)
CA (1) CA1341502C (sv)
CZ (3) CZ281756B6 (sv)
DE (3) DE411678T1 (sv)
DK (4) DK172953B1 (sv)
ES (1) ES8800049A1 (sv)
FI (2) FI104261B (sv)
GE (1) GEP19970775B (sv)
GR (1) GR852890B (sv)
HK (2) HK105693A (sv)
HU (1) HU216079B (sv)
IL (1) IL77081A (sv)
LV (2) LV10505B (sv)
MD (1) MD1639C2 (sv)
NO (1) NO304469B1 (sv)
PL (2) PL154180B1 (sv)
PT (1) PT81590B (sv)
SK (2) SK168799A3 (sv)
UA (1) UA44882C2 (sv)
WO (1) WO1986003520A1 (sv)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) * 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4677195A (en) * 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
EP0236059B1 (en) * 1986-02-27 1994-04-27 Snow Brand Milk Products Co. Ltd. Preparation of erythropoietin-producing cells and production process of erythropoietin using same
DK173067B1 (da) * 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
NZ221790A (en) * 1986-09-12 1990-07-26 Genentech Inc Method for the continuous production of a heterologous protein in a eukaryotic host cell
US4954437A (en) * 1986-09-15 1990-09-04 Integrated Genetics, Inc. Cell encoding recombinant human erythropoietin
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5888774A (en) * 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
DE69638058D1 (de) 1995-06-15 2009-11-26 Crucell Holland Bv Verpackungssysteme für humane rekombinante Adenoviren zur Gentherapie
EP0752474A1 (en) * 1995-07-07 1997-01-08 Boehringer Mannheim Gmbh Nucleic acid coding for CMP-N-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins
JPH10510434A (ja) * 1995-07-07 1998-10-13 ベーリンガー マンハイム ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｍｐ−ｎ−アセチルノイラミン酸ヒドロキシラーゼをコードする核酸及び修飾糖タンパク質の産生のためのその使用
DE19535571A1 (de) 1995-09-14 1997-03-20 Boehringer Mannheim Gmbh Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten
US5952226A (en) * 1996-11-05 1999-09-14 Modex Therapeutiques Hypoxia responsive EPO producing cells
WO1998041226A1 (de) 1997-03-18 1998-09-24 Roche Diagnostics Gmbh Pharmazeutische kombinationspräparate enthaltend erythropoietin und eisenpräparate
EP0885613A1 (de) 1997-06-21 1998-12-23 Roche Diagnostics GmbH Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin
KR100622203B1 (ko) 1997-07-23 2006-09-07 로셰 디아그노스틱스 게엠베하 내인성 유전자 활성화에 의해 사람 단백질을 생성시키는 사람 세포주를 확인하는 방법
US6548296B1 (en) 1997-07-23 2003-04-15 Roche Diagnostics Gmbh Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof
CA2298412C (en) * 1997-07-23 2010-10-19 Roche Diagnostics Gmbh Identification of human cell lines for the production of human proteins by endogenous gene activation
KR100641969B1 (ko) 1997-07-23 2006-11-06 로셰 디아그노스틱스 게엠베하 내인성 유전자 활성화에 의한 에리트로포이에틴의제조방법
CN1151258C (zh) * 1997-07-23 2004-05-26 罗切诊断学有限公司 通过内源基因活化制备促红细胞生成素
ES2208798T3 (es) * 1997-09-01 2004-06-16 Aventis Pharma Deutschland Gmbh Eritropoyetina humana recombinante con un perfil de glicosilacion ventajoso.
AR019025A1 (es) 1998-04-09 2001-12-26 Roche Diagnostics Gmbh Uso de eritropoyetina en bajas dosis para producir un preparado farmaceutico para el tratamiento de hemocromatosis, preparado farmaceutico combinadoutilizado segun dicho uso y envase farmaceutico unitario que contiene al referido preparado farmaceutico combinado
BR9905867A (pt) 1998-11-06 2001-01-23 Bio Sidus S A Linhagem celular produtora de eritropoietina humana recombinante e a eritropoietina humana recombinante produzida por esta célula
BR9917606A (pt) 1998-11-06 2002-12-31 Bio Sidus S A Procedimento para a purificação de eritropoetina humana recombinante a partir de sobrenadantes de cultivo de células e eritropoetina humana recombinante obtida com tal procedimento
US6777205B1 (en) 1998-11-06 2004-08-17 Sterrenbeld Biotechnologie North America, Inc. Host cells expressing recombinant human erythropoietin
BR9905868A (pt) 1998-11-06 2001-01-23 Bio Sidus S A Procedimento de cultivo massivo de células de mamìfero para a obtenção de eritropoetina humana, recombinante e a eritropoetina humana recombinante obtida com tal procedimento
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US8236561B2 (en) 1999-04-15 2012-08-07 Crucell Holland B.V. Efficient production of IgA in recombinant mammalian cells
US7297680B2 (en) 1999-04-15 2007-11-20 Crucell Holland B.V. Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US6855544B1 (en) 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7527961B2 (en) 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
AU2002233230B2 (en) 2000-12-20 2007-02-01 F. Hoffmann-La Roche Ag Erythropoietin conjugates
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
KR100505152B1 (ko) * 2001-09-10 2005-08-03 (주)가이아진 아스코르브산을 이용한 에리트로포이에틴의 생산방법
US6930086B2 (en) 2001-09-25 2005-08-16 Hoffmann-La Roche Inc. Diglycosylated erythropoietin
EP1465987B1 (en) 2001-12-07 2008-01-23 Crucell Holland B.V. Production of viruses, viral isolates and vaccines
CA2471363C (en) 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
US7459435B2 (en) 2002-08-29 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
CA2496317C (en) 2002-09-11 2014-02-18 Fresenius Kabi Deutschland Gmbh Method of producing hydroxyalkyl starch derivatives
EP1681303B1 (en) 2002-09-11 2013-09-04 Fresenius Kabi Deutschland GmbH HASylated polypeptides, especially HASylated erythropoietin
AU2003273413A1 (en) 2002-10-08 2004-05-04 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US7459436B2 (en) 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
CA2520891C (en) 2003-05-09 2014-07-08 Crucell Holland B.V. Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US7645733B2 (en) 2003-09-29 2010-01-12 The Kenneth S. Warren Institute, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
ES2606068T3 (es) 2003-12-30 2017-03-17 Augustinus Bader Eritropoyetina para uso en el tratamiento de heridas o el trasplante de células
DE102004063927A1 (de) 2004-01-23 2005-12-15 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
SG151261A1 (en) 2004-03-11 2009-04-30 Fresenius Kabi De Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
JP5396019B2 (ja) 2004-03-11 2014-01-22 フレゼニウス・カビ・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ヒドロキシアルキルデンプンとタンパク質とのコンジュゲート
GB0507123D0 (en) * 2005-04-08 2005-05-11 Isis Innovation Method
EP1762250A1 (en) 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
AR053416A1 (es) * 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
CN101365719A (zh) 2006-01-18 2009-02-11 中外制药株式会社 唾液酸的去除方法及去唾液酸促红细胞生成素的制备方法
DE102006004008A1 (de) 2006-01-27 2007-08-02 Hannelore Prof. Dr. Dr. Ehrenreich Verfahren zur Behandlung und/oder Prophylaxe von Multipler Sklerose, sowie Verwendung von Erythropoietin zur Herstellung eines Arzneimittels zur intermittierenden Behandlung und/oder intermittierenden Prophylaxe von Multipler Sklerose
CN101213206A (zh) * 2006-03-07 2008-07-02 雷格内泰克公司 通过电磁刺激哺乳动物活细胞生产的天然糖基化哺乳动物生物分子
WO2007108505A1 (ja) 2006-03-22 2007-09-27 Chugai Seiyaku Kabushiki Kaisha エリスロポエチン溶液製剤
PT2054074E (pt) 2006-08-04 2014-11-07 Prolong Pharmaceuticals Llc Eritropoietina modificada
WO2009010107A1 (en) 2007-07-19 2009-01-22 Hannelore Ehrenreich Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
EP2095829A1 (en) 2008-02-27 2009-09-02 LEK Pharmaceuticals D.D. Selenium containing modifying agents and conjugates
DE102008002209A1 (de) 2008-06-04 2009-12-10 Evonik Degussa Gmbh Verfahren zur Aufreinigung von Erythropoietin
DE102008002210A1 (de) 2008-06-04 2009-12-10 Evonik Degussa Gmbh Verfahren zur fermentativen Herstellung von Erythropoietin
JP5632376B2 (ja) 2008-09-23 2014-11-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ エリスロポエチンの精製
DE102008054716A1 (de) 2008-12-16 2010-06-17 Evonik Degussa Gmbh Inprozesskontrolle in einem Verfahren zur Herstellung von EPO
US20100272816A1 (en) 2009-04-27 2010-10-28 Wolfgang Rudinger Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
CN102712688B (zh) 2009-09-23 2015-06-24 通益制药有限公司 重组人红细胞生成素(epo)的纯化方法、由此纯化的epo以及包含纯化的epo的药物组合物
WO2017068051A1 (en) 2015-10-21 2017-04-27 Lek Pharmaceuticals D.D. Peg-based dendron and process for producing the same
CN106906359B (zh) 2015-12-22 2018-12-11 理查德.亨威克 从硅酸盐矿物收取锂
CN110446499A (zh) 2017-03-20 2019-11-12 豪夫迈·罗氏有限公司 一种体外糖基工程化红细胞生成刺激蛋白的方法
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US439780A (en) * 1890-11-04 Method of and apparatus for casting ingots
US3865801A (en) * 1973-06-15 1975-02-11 Atomic Energy Commission Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
JPS5455790A (en) * 1977-10-05 1979-05-04 Tomoyuki Tajima Production of erythropoetin
JPS5653696A (en) * 1979-10-09 1981-05-13 Ajinomoto Co Inc Isolation of erythropoietin by adsorption
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
US4419446A (en) * 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
JPS6043395A (ja) * 1983-08-19 1985-03-07 Sumitomo Chem Co Ltd エリスロポエチンの製造法
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IT1185503B (it) * 1984-01-11 1987-11-12 Univ New York Cloni di odna di eritropietina umana
JPS60215632A (ja) * 1984-04-12 1985-10-29 Japan Found Cancer エリスロポエチンの製造法
US4732889A (en) * 1985-02-06 1988-03-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
JPH062070B2 (ja) * 1988-07-06 1994-01-12 農林水産省食品総合研究所長 ▲ｏ下−▼アシルアミノ酸の製造方法

Also Published As

Publication number Publication date
DE3582732D1 (de) 1991-06-06
PL256589A1 (en) 1986-10-21
DE411678T1 (de) 1991-10-17
JPH01257480A (ja) 1989-10-13
ES8800049A1 (es) 1987-10-16
JPH02104284A (ja) 1990-04-17
DE3585161D1 (de) 1992-02-20
SK279765B6 (sk) 1999-03-12
HK105693A (en) 1993-10-15
MD940371A (en) 1996-06-28
KR890001011B1 (en) 1989-04-18
FI104261B1 (sv) 1999-12-15
CZ286557B6 (cs) 2000-05-17
WO1986003520A1 (en) 1986-06-19
PL154180B1 (en) 1991-07-31
FI863044A0 (fi) 1986-07-24
UA44882C2 (uk) 2002-03-15
DK173254B1 (da) 2000-05-22
JPH0655144B2 (ja) 1994-07-27
NO863050D0 (no) 1986-07-28
SK880485A3 (en) 1999-03-10
NO863050L (no) 1986-07-28
PT81590B (pt) 1987-10-20
SK281799B6 (sk) 2001-08-06
IL77081A0 (en) 1986-04-29
EP0205564B1 (en) 1991-05-02
EP0205564B2 (en) 2000-06-21
DK200000527A (da) 2000-03-29
KR870700099A (ko) 1987-02-28
AU621535B2 (en) 1992-03-19
CZ880485A3 (en) 1996-08-14
ES549539A0 (es) 1987-10-16
GEP19970775B (en) 1997-01-27
FI105347B (sv) 2000-07-31
HU216079B (hu) 1999-04-28
DK173293B1 (da) 2000-06-13
PL157926B1 (pl) 1992-07-31
EP0411678B2 (en) 2000-01-12
DK199901147A (da) 1999-08-20
EP0411678B1 (en) 1992-01-08
CZ281756B6 (cs) 1997-01-15
PT81590A (en) 1986-01-01
CA1341502C (en) 2006-03-21
FI863044A (fi) 1986-07-24
EP0205564A1 (en) 1986-12-30
LV10507B (lv) 1996-06-20
EP0205564A4 (en) 1987-12-14
CZ287620B6 (cs) 2001-01-17
FI19992064A (sv) 1999-09-27
LV10507A (lv) 1995-02-20
JPH02442A (ja) 1990-01-05
MD1639B2 (en) 2001-03-31
DK368786D0 (da) 1986-08-01
HK105593A (en) 1993-10-15
DK172953B1 (da) 1999-10-18
SK168799A3 (en) 2001-08-06
DK175826B1 (da) 2005-03-14
MD1639C2 (ro) 2001-10-31
JPH07184681A (ja) 1995-07-25
GR852890B (sv) 1986-04-03
AU5313486A (en) 1986-07-01
NO304469B1 (no) 1998-12-21
LV10505A (lv) 1995-02-20
HUT40706A (en) 1987-01-28
CZ127496A3 (cs) 2000-02-16
DK368786A (da) 1986-08-01
DK95197A (da) 1997-08-20
FI104261B (sv) 1999-12-15
IL77081A (en) 1999-10-28
EP0411678A1 (en) 1991-02-06
ATE63137T1 (de) 1991-05-15
ATE71408T1 (de) 1992-01-15

Similar Documents

Publication Publication Date Title
LV10505B (en) Method for the production of erytropoietin
EP0830376B1 (de) Verfahren zur herstellung von erythropoietin frei von tierischen proteinen
EP0409113B1 (de) Muteine des menschlichen Erythropoetins, ihre Herstellung und ihre Verwendung
AT389892B (de) Dna-sequenz mit einem gen, das fuer human-interleukin-2 codiert
DE69933699T2 (de) Verfahren zur produktion rekombinanter proteine in säugetierzellen durch co-expression mit fetuin
DE69034104T2 (de) Herstellung von heteropolymeren Proteinen
DD251788A5 (de) Verfahren zur Herstellung eines menschlichen cDNA-Klons
SK46598A3 (en) Recombinant dna plasmid vector, mammalian cell transformed with this vector, recombinant human erythropoietin, and method of its production
DD279687A5 (de) Verfahren zur herstellung von erythropoietin
EP0256302B1 (de) Verfahren zur Herstellung von humanem Antithrombin-III (ATIII) und dafür geeignete Vektoren
DE69533840T2 (de) Verbesserter expressionsvektor für die herstellung rekombinanter proteine
EP1651669A1 (de) Perfusionsverfahren für die produktion von erythropoietin
JPH0144317B2 (sv)
AU5711199A (en) Method for the production of erythropoietin
DD255359A5 (de) Verfahren zur bestimmung eines spezifischen einzelstraengigen polynuclebtids unbekannter sequenz
DD251786A5 (de) Verfahren zur Herstellung eines Polypeptids
DE10152660A1 (de) Verwendung einer Nukleotidsequenz kodierend für ein intrazelluläres Hyaluronsäure-bindendes Protein
DD257271A1 (de) Verfahren zur herstellung von menschlichem wachstumshormon (somatotropin)